Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to ...

The US Food and Drug Administration has approved a higher 2-mg dose of the GLP-1 agonist semaglutide (Ozempic, Novo Nordisk) for adults with type 2 diabetes, giving a higher-dose alternative to the ...

Novo Nordisk officials believe the new therapy will fufill an unmet need for patients with type 2 diabetes and obesity who need a GLP-1 receptor agonist but do not wish to use an injectable drug. FDA ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SAN DIEGO — A weekly glucagon/GLP-1 dual receptor ...

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy ®) achieved significant weight loss, with one in three study participants losing 20% or more body weight 1 ** Oral semaglutide 25 mg ...

New data from OASIS 4 on oral semaglutide 25 mg to reveal insights on cardiometabolic health among adults with obesity or overweight Additional trial insights into impact on ability to do everyday ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a once-weekly 2 mg semaglutide injection in conjunction with diet and exercise to lower ...

A novel antidiabetic agent beat out a tried-and-true favorite when it came to slashing HbA1c, according to the phase III SURPASS-2 trial. In an open-label trial of adults with type 2 diabetes, ...

Bagsværd, Denmark, 29 December 2020 – Novo Nordisk today announced the submission of a label extension application to the European Medicines Agency (EMA) for the existing marketing authorisation for ...